

# COGNITE Alzheimer's Clinical Trial

## AZ THERAPIES



### THE PURPOSE

To evaluate the safety and effectiveness of two medications on the progression of early Alzheimer's disease.

**Name of Investigator** | Allan Anderson, MD

**Name of Project** | A Phase III Safety and Efficacy Study of ALZT-OPI

**Total number of participants to-date** | 282

**Timeline of the project** | 3 years

**Target population** | Individuals with early stage Alzheimer's disease or mild cognitive impairment

### WHAT DID PEOPLE DO IF THEY WERE INVOLVED WITH THE PROJECT?

Participants agree to medical, cognitive, and physical evaluations for 5 visits over 72 weeks in addition to potentially taking up to two common medications. Study partners also report on changes seen in their loved ones at each visit.

### WHAT DID PARTICIPANTS TAKE AWAY FROM THEIR INVOLVEMENT?

Participants receive ongoing regular monitoring from their physician and up to two common medications that may slow the progression of their disease.

### WHAT ISSUES OR FINDINGS WERE DISCOVERED DURING THE PROJECT?

**Finding:** The trial is still ongoing. No findings have been released at this time.

**Application for senior living professionals:** Common medications are being repurposed for use in early stage individuals. Professionals should be aware of the latest treatment hypotheses so that they are able to fully inform individuals they serve.

